These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 31828875)

  • 1. Pharmaceutically treated comorbidities and associated healthcare costs among triptan users in Switzerland: A pharmacoepidemiological study from a nationwide health insurance database.
    Huber CA; Agosti R; Näpflin M; Blozik E
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):279-287. PubMed ID: 31828875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Migraine burden and costs in France: a nationwide claims database analysis of triptan users.
    Donnet A; Emery C; Aly S; Allaf B; Cayre F; Mahieu N; Gourmelen J; Levy P; Fagnani F
    J Med Econ; 2019 Jul; 22(7):616-624. PubMed ID: 30836035
    [No Abstract]   [Full Text] [Related]  

  • 3. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors Associated with Direct Health Care Costs Among Patients with Migraine.
    Bonafede M; Cai Q; Cappell K; Kim G; Sapra SJ; Shah N; Widnell K; Winner P; Desai P
    J Manag Care Spec Pharm; 2017 Nov; 23(11):1169-1176. PubMed ID: 29083975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptan persistency among newly initiated users in a pharmacy claims database.
    Katić BJ; Rajagopalan S; Ho TW; Chen YT; Hu XH
    Cephalalgia; 2011 Mar; 31(4):488-500. PubMed ID: 20937605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptans use and overuse: A pharmacoepidemiology study from the French health insurance system database covering 4.1 million people.
    Braunstein D; Donnet A; Pradel V; Sciortino V; Allaria-Lapierre V; Lantéri-Minet M; Micallef J
    Cephalalgia; 2015 Nov; 35(13):1172-80. PubMed ID: 25667299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database - A cohort study.
    Zebenholzer K; Gall W; Gleiss A; Pavelic AR; Wöber C
    Headache; 2022 May; 62(5):604-612. PubMed ID: 35593784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use and overuse of triptans in Austria - a survey based on nationwide healthcare claims data.
    Zebenholzer K; Gall W; Wöber C
    J Headache Pain; 2018 May; 19(1):34. PubMed ID: 29777424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of use and health expenses associated with triptans among adults with migraines.
    Wu J; Noxon V; Lu ZK
    Clin J Pain; 2015 Aug; 31(8):673-9. PubMed ID: 25185875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in Triptan Usage in Korea: A Population-Based Cohort Study.
    Ha WS; Jeong J; Song S; Yum J; Chu MK
    J Korean Med Sci; 2024 Aug; 39(31):e222. PubMed ID: 39137809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost of illness and labour market disaffiliation among patients with migraine discontinuing triptan treatment: A Danish nationwide register study from 1995 to 2021.
    Ashina M; Steiner TJ; Hansen JM; Hauberg DS; Lønberg US; Spanggaard M; Olsen J; Stallknecht SE; Hansen TF
    Cephalalgia; 2024 Sep; 44(9):3331024241269758. PubMed ID: 39324203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs and utilization of triptan users who receive drug prophylaxis for migraine versus triptan users who do not receive drug prophylaxis.
    Etemad LR; Yang W; Globe D; Barlev A; Johnson KA
    J Manag Care Pharm; 2005 Mar; 11(2):137-44. PubMed ID: 15766320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results of a 2-year retrospective cohort study of newly prescribed triptan users in European nationwide practice databases.
    Ng-Mak DS; Chen YT; Ho TW; Stanford B; Roset M
    Cephalalgia; 2012 Sep; 32(12):875-87. PubMed ID: 22833612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Lee JH; Shewale AR; Barthold D; Devine B
    Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Triptan overuse in the Dutch general population: a nationwide pharmaco-epidemiology database analysis in 6.7 million people.
    Dekker F; Wiendels NJ; de Valk V; van der Vliet C; Knuistingh Neven A; Assendelft WJ; Ferrari MD
    Cephalalgia; 2011 Jun; 31(8):943-52. PubMed ID: 21593190
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The estimation power of alternative comorbidity indices.
    Baser O; Palmer L; Stephenson J
    Value Health; 2008; 11(5):946-55. PubMed ID: 18489502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.